Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder

Phase 3positiveHETLIOZPositive

AI Analysis

Summary

Vanda Pharmaceuticals announced positive Phase III results for HETLIOZ (tasimelteon) in Delayed Sleep-Wake Phase Disorder. The trial met its primary endpoints, supporting the drug's efficacy in this indication.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Importance:7/10

Sentiment:

0.80

Phase 3Clinical TrialPositive ResultsSleep DisorderFDA

Related Companies

$VNDA

Read the original article

Published by yahoo_finance on September 29, 2026 10:45 PM

Read Original